Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription 24.08.2026 1 Am J Pathol 2 Dig Dis Sci 3 Endoscopy 4 Eur Radiol 2 Gastroenterology 2 Indian J Gastroenterol 2 J Gastroenterol Hepatol 6 J Hepatol 1 J Pediatr 2 Lancet 1 PLoS Comput Biol 6 PLoS One 2 Proc Natl Acad Sci U S A 2 Transplant Proc

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Pathol

1. BANERJEE S, Kim J, Smith MR, Wang YI, et al
   Mitochondrial ROS-induced metabolic alterations differentially regulate ferroptosis vulnerability of hepatocytes.
   Am J Pathol. 2026 Aug 19:S0002-9440(26)00234.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

2. SOUZA M
   Placebo-Arm Cirrhosis Incidence in Fibrotic MASH: A Trial-Based Benchmark.
   Dig Dis Sci. 2026 Aug 21. doi: 10.1007/s10620-026-10189.
   PubMed        
   
   
3. HUANG YJ, Chang CH, Lee SW, Tung CF, et al
   Higher Off-Therapy Relapse Risk with Tenofovir Alafenamide than Entecavir in Non-cirrhotic HBeAg-Negative Chronic Hepatitis B: Insights from End-of-Treatment qHBsAg Stratification.
   Dig Dis Sci. 2026 Aug 18. doi: 10.1007/s10620-026-10188.
   PubMed         Abstract available
   
   

   
   Endoscopy

4. BRIGIDA M, Crino SF, Alfadda A, Dell'Anna G, et al
   Comparative efficacy and safety of endoscopic treatments for gastric varices: a systematic review and network meta-analysis.
   Endoscopy. 2026;58:1026-1035.
   PubMed         Abstract available
   
   
5. RERKNIMITR R
   Distinguishing the mechanisms of recurrent biliary obstruction among antegrade transpapillary stenting versus hepaticogastrostomy versus choledochoduodenostomy.
   Endoscopy. 2026;58:1061.
   PubMed        
   
   
6. NIE H, Wang F, Ailijiang B, Zhou F, et al
   Correction: Delayed biliary hemorrhage following transjugular intrahepatic portosystemic shunt.
   Endoscopy. 2026;58.
   PubMed        
   
   

   
   Eur Radiol

7. SONG BG, Jeong WK, Goh MJ, Kang W, et al
   Risk-stratified MRI surveillance for hepatocellular carcinoma in cirrhosis: a prospective cohort study.
   Eur Radiol. 2026 Aug 15. doi: 10.1007/s00330-026-12820.
   PubMed         Abstract available
   
   
8. YANG HK, Lee S, Lee MY, Jeong B, et al
   Visualization quality and effectiveness of noncontrast-abbreviated magnetic resonance imaging for hepatocellular carcinoma surveillance in cirrhotic patients with ultrasound visualization score C.
   Eur Radiol. 2026 Aug 20. doi: 10.1007/s00330-026-12822.
   PubMed         Abstract available
   
   
9. SHEN Y, Jiang D, Zhu A, Fan Y, et al
   Quantitative ultrasound-derived fat fraction for hepatic steatosis in MASLD using liver biopsy as the reference standard: a dual-center study.
   Eur Radiol. 2026 Aug 20. doi: 10.1007/s00330-026-12807.
   PubMed         Abstract available
   
   
10. XU D, Li M, Huang M, Zhao Q, et al
    Incidence and risk factors of complications following microsecond and nanosecond pulsed electric field ablation for hepatocellular carcinoma: a 10-year multicenter cohort study.
    Eur Radiol. 2026 Aug 21. doi: 10.1007/s00330-026-12826.
    PubMed         Abstract available
    
    

    
    Gastroenterology

11. LIU A
    Carvedilol Continues to Win: A Target Trial Emulation Study Comparing Carvedilol Against Other Nonselective B-Blockers in Cirrhosis.
    Gastroenterology. 2026 Aug 21:S0016-5085(26)07183.
    PubMed        
    
    
12. PIRZADA SA, Ghany MG
    HBsAg Loss and Hepatocellular Carcinoma Surveillance: One Size Does Not Fit All.
    Gastroenterology. 2026 Aug 17:S0016-5085(26)07166.
    PubMed        
    
    

    
    Indian J Gastroenterol

13. KATREVULA A, Kalapala R, Agrawal S, Jagtap N, et al
    Oral semaglutide for weight loss and liver fibrosis in overweight and obesity: A randomized controlled trial.
    Indian J Gastroenterol. 2026;45:872-883.
    PubMed         Abstract available
    
    
14. TYAGI K, Bhatt SP, Ansari IA, Pandey S, et al
    Correlation of hepatic steatosis and fibrosis with microvascular complications among obese and non-obese individuals with T2D and MASLD.
    Indian J Gastroenterol. 2026 Aug 19. doi: 10.1007/s12664-026-02037.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

15. TADA T, Matono T, Kumada T
    Response to the Letter Regarding "Methodological Considerations in Real-World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma".
    J Gastroenterol Hepatol. 2026 Aug 18. doi: 10.1111/jgh.70674.
    PubMed        
    
    
16. JIANG J, Wang B, Wang Q, Ma X, et al
    AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis.
    J Gastroenterol Hepatol. 2026 Aug 16. doi: 10.1111/jgh.70670.
    PubMed         Abstract available
    
    

    
    J Hepatol

17. 
    Baveno VIII - Advancing Consensus in Portal Hypertension.
    J Hepatol. 2026 Aug 6:S0168-8278(26)02778-9. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
18. WANG KQ, Xie WF
    Reply to "Rifaximin and the DCA-serotonin axis in cirrhotic portal hypertension: how much of the benefit is bile-acid specific?".
    J Hepatol. 2026 Aug 21:S0168-8278(26)02858-8. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
19. SHU H, Wu D, Xie L, Wang G, et al
    Fusobacterium nucleatum alleviates alcohol-associated liver disease through mannose-mediated elevation of Fbp1 and modulation of gut microbiota.
    J Hepatol. 2026;85:463-478.
    PubMed         Abstract available
    
    
20. ORTEGA-RIBERA M, Brenig R, Bernsmeier C, Szabo G, et al
    Uncovering immune dysfunction in ACLF: Cellular mechanisms, molecular pathways, and therapeutic frontiers.
    J Hepatol. 2026;85:612-629.
    PubMed         Abstract available
    
    
21. 
    EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis.
    J Hepatol. 2026 May 27:S0168-8278(26)00193-5. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
22. DONG C, Zhong X, Peng Q, Muller Z, et al
    Impaired glycoRNA biogenesis in metabolic-dysfunction associated steatotic liver disease.
    J Hepatol. 2026;85:551-566.
    PubMed         Abstract available
    
    

    
    J Pediatr

23. ELDREDGE JA, Dhawan A, Deheragoda M, Heaton ND, et al
    Sudden Acute Liver Failure in Citrullinemia type 1: An Argument for Earlier Liver Transplantation?
    J Pediatr. 2026 Jun 2:115181. doi: 10.1016/j.jpeds.2026.115181.
    PubMed         Abstract available
    
    

    
    Lancet

24. SUN HC, Zhu XD, Shen F, Song TQ, et al
    Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.
    Lancet. 2026;408:699-710.
    PubMed         Abstract available
    
    
25. FORNER A
    TALENTOP study: a new era for conversion surgery in advanced hepatocellular carcinoma?
    Lancet. 2026;408:668-669.
    PubMed        
    
    

    
    PLoS Comput Biol

26. LAN W, Wang D, Chen W, Yan X, et al
    ERFMTDA: Predicting tsRNA-disease associations using an enhanced rotative factorization machine.
    PLoS Comput Biol. 2026;22:e1014594.
    PubMed         Abstract available
    
    

    
    PLoS One

27. SHAHID K, Shahzad MI, Ehsan M, Hu RS, et al
    Proteomic characterization of adult Fasciola gigantica recovered from naturally infected buffaloes in Punjab Pakistan.
    PLoS One. 2026;21:e0356497.
    PubMed         Abstract available
    
    
28. WANG T, Huang Q, Wang Y, Li C, et al
    Integrated liver transcriptomic data reveal differences in aging-associated regulation between metabolic dysfunction-associated steatotic liver disease and normal liver aging.
    PLoS One. 2026;21:e0356820.
    PubMed         Abstract available
    
    
29. HJORTH M, Forsberg A
    Aspects of implementing a nurse-based follow-up of patients with liver cirrhosis: A qualitative study.
    PLoS One. 2026;21:e0356782.
    PubMed         Abstract available
    
    
30. ZHAO X, He Y, Zhang Y, Liu D, et al
    Streptomyces-linked exercise gene networks orchestrate immune exclusion and determine immunotherapy response in hepatocellular carcinoma.
    PLoS One. 2026;21:e0356502.
    PubMed         Abstract available
    
    
31. ZABOR EC, Yesiltas YS, Singh AD
    Systemic surveillance for uveal melanoma: Approach to optimization.
    PLoS One. 2026;21:e0355405.
    PubMed         Abstract available
    
    
32. KARAGYOZOV PI, Dobreva IK, Zhecheva IB
    Endoscopic ultrasound-guided liver biopsy using a 22G fine-needle biopsy needle and slow pull technique: A tertiary center experience.
    PLoS One. 2026;21:e0356373.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

33. ZHANG D, Liu X, Ma D, Liao L, et al
    Macrophages diverge into profibrotic SAMs and proresolving ReM2 cells to regulate liver fibrosis.
    Proc Natl Acad Sci U S A. 2026;123:e2611441123.
    PubMed         Abstract available
    
    
34. MU J, Dong J, Chen J, Sima P, et al
    CXCR4-targeted dual softener for inducing senescence therapy in hepatic fibrosis.
    Proc Natl Acad Sci U S A. 2026;123:e2600215123.
    PubMed         Abstract available
    
    

    
    Transplant Proc

35. MESTER P, Schmid S, Muller M, Pavel V, et al
    Successful Heart and Renal Allograft Transplantation From Patients With Child-Pugh Class C Cirrhosis.
    Transplant Proc. 2026 Aug 19:S0041-1345(26)00376.
    PubMed         Abstract available
    
    
36. LEE JE, Hwang YJ, Jung H, Lim DG, et al
    Effects of Dexmedetomidine Preconditioning on Hepatic Ischemia-Reperfusion Injury in Rats.
    Transplant Proc. 2026 Aug 20:S0041-1345(26)00393.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum